An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions
- 25 July 2025
- journal article
- review article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 141, 111461
Abstract
No abstract availableKeywords
Funding Information
- Iran University of Medical Sciences
This publication has 45 references indexed in Scilit:
- Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitorsCellular and Molecular Life Sciences, 2024
- FDA gives breakthrough designation for psychedelic treatmentMental Health Weekly, 2024
- Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybinMed, 2024
- Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research LandscapeJAMA Psychiatry, 2023
- The need for establishing best practices and gold standards in psychedelic medicineJournal of Affective Disorders, 2023
- IUPHAR – invited review - Ibogaine – A legacy within the current renaissance of psychedelic therapyPharmacological Research, 2023
- Psychedelic Drug Legislative Reform and Legalization in the USJAMA Psychiatry, 2023
- Mescaline: The forgotten psychedelicNeuropharmacology, 2022
- MDMA and memory, addiction, and depression: dose-effect analysisPsychopharmacology, 2022
- Ketamine for the treatment of addiction: Evidence and potential mechanismsNeuropharmacology, 2018